U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H20N2O3S
Molecular Weight 356.439
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIOGLITAZONE

SMILES

CCC1=CC=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)N=C1

InChI

InChIKey=HYAFETHFCAUJAY-UHFFFAOYSA-N
InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)

HIDE SMILES / InChI

Molecular Formula C19H20N2O3S
Molecular Weight 356.439
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/actos-pioglitazone-342726 | https://www.drugbank.ca/drugs/DB01132 | https://www.drugs.com/cdi/pioglitazone.html | https://www.ncbi.nlm.nih.gov/pubmed/25760794

Pioglitazone (brand name Actos) is a prescription drug of the thiazolidinedione class with hypoglycemic action used in the treatment of type 2 diabetes. Pioglitazone selectively stimulates the nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent PPAR-α. It modulates the transcription of the genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissue, and the liver. As a result, pioglitazone reduces insulin resistance in the liver and peripheral tissues, decreases gluconeogenesis in the liver, and reduces the quantity of glucose and glycated hemoglobin in the bloodstream. Pioglitazone is used to lower blood glucose levels in the treatment of diabetes mellitus type 2 (T2DM) either alone or in combination with a sulfonylurea, metformin, or insulin. Pioglitazone cannot be used in patients with a known hypersensitivity to pioglitazone, other thiazolidinediones or any of components of its pharmaceutical forms. It is ineffective and possibly harmful to diabetes mellitus type 1 and diabetic ketoacidosis. Pioglitazone can cause fluid retention and peripheral edema. As a result, it may precipitate congestive heart failure (which worsens with fluid overload in those at risk). It may cause anemia. Mild weight gain is common due to increase in subcutaneous adipose tissue. In studies, patients on pioglitazone had an increased proportion of upper respiratory tract infection, sinusitis, headache, myalgia and tooth problems.

Originator

Curator's Comment: # Takeda Chemical Industries, Ltd

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACTOS

Approved Use

Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (1.1, 14) Important Limitation of Use: •Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1.2) 1.1 Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)

Launch Date

1999
Primary
ACTOS

Approved Use

Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (1.1, 14) Important Limitation of Use: •Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1.2) 1.1 Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)

Launch Date

1999
Primary
ACTOS

Approved Use

Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (1.1, 14) Important Limitation of Use: •Not for treatment of type 1 diabetes or diabetic ketoacidosis. (1.2) 1.1 Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [see Clinical Studies (14)

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
890 ng/mL
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PIOGLITAZONE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
8662 ng × h/mL
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PIOGLITAZONE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
12.6 h
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PIOGLITAZONE plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
0.75 mg/kg 1 times / day multiple, oral
MTD
Dose: 0.75 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.75 mg/kg, 1 times / day
Sources: Page: p.7, 9
unhealthy, 5-12
n = 18
Health Status: unhealthy
Condition: Autistic disorder|Asperger syndrome
Age Group: 5-12
Sex: M+F
Population Size: 18
Sources: Page: p.7, 9
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.983, 984
unhealthy, 58.1
n = 60
Health Status: unhealthy
Condition: Nonalcoholic Steatohepatitis and Prediabetes|Type 2 Diabetes Mellitus
Age Group: 58.1
Sex: M+F
Population Size: 60
Sources: Page: p.983, 984
Disc. AE: Edema, ALT increased...
AEs leading to
discontinuation/dose reduction:
Edema (mild, 1.67%)
ALT increased (grade 2-4, 1.67%)
Sources: Page: p.983, 984
180 mg 1 times / day multiple, oral
Overdose
Dose: 180 mg, 1 times / day
Route: oral
Route: multiple
Dose: 180 mg, 1 times / day
Sources: Page: p.21
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.21
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Disc. AE: Congestive heart failure, Edema...
AEs leading to
discontinuation/dose reduction:
Congestive heart failure
Edema
Hepatic failure (grade 5)
Fractures
Bladder cancer
Hypoglycemia
Macular edema
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
ALT increased grade 2-4, 1.67%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.983, 984
unhealthy, 58.1
n = 60
Health Status: unhealthy
Condition: Nonalcoholic Steatohepatitis and Prediabetes|Type 2 Diabetes Mellitus
Age Group: 58.1
Sex: M+F
Population Size: 60
Sources: Page: p.983, 984
Edema mild, 1.67%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.983, 984
unhealthy, 58.1
n = 60
Health Status: unhealthy
Condition: Nonalcoholic Steatohepatitis and Prediabetes|Type 2 Diabetes Mellitus
Age Group: 58.1
Sex: M+F
Population Size: 60
Sources: Page: p.983, 984
Bladder cancer Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Congestive heart failure Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Edema Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Fractures Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Hypoglycemia Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Macular edema Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
Hepatic failure grade 5
Disc. AE
45 mg 1 times / day multiple, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: multiple
Dose: 45 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources: Page: p.1
PubMed

PubMed

TitleDatePubMed
15-Deoxy-delta 12,14-prostaglandin J2 and thiazolidinediones activate the MEK/ERK pathway through phosphatidylinositol 3-kinase in vascular smooth muscle cells.
2001 Dec 28
The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells.
2001 Jan
Bisphenol a diglycidyl ether (BADGE) suppresses tumor necrosis factor-alpha production as a PPARgamma agonist in the murine macrophage-like cell line, RAW 264.7.
2002
Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.
2002 Apr
Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.
2002 Jan 11
Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db/db mice.
2003 May
Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC-MS/MS.
2003 Sep 15
Effects of PPARg agonist pioglitazone on rat hepatic fibrosis.
2004 Apr 1
Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha.
2004 Aug
Peroxisome proliferator-activated receptor gamma ligands suppress liver carcinogenesis induced by diethylnitrosamine in rats.
2004 Dec 1
Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes.
2004 Jan
Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.
2004 Jan 1
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
2005 Aug
Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation.
2005 Sep
Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.
2005 Sep 2
Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat.
2006 Aug 29
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.
2006 Jan 10
Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion.
2006 Jan 13
[Resveratrol inhibits expression of EMMPRIN from macrophages].
2006 Jul
Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated p70 ribosomal S6 kinase-1 inhibition: role for Zf9 dephosphorylation.
2006 Jul
Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats.
2006 Jul
Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
2006 Jun
Gene expression analysis of troglitazone reveals its impact on multiple pathways in cell culture: a case for in vitro platforms combined with gene expression analysis for early (idiosyncratic) toxicity screening.
2006 Mar-Apr
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis.
2006 May
The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
2006 Nov 7
Acetaldehyde inhibits PPARgamma via H2O2-mediated c-Abl activation in human hepatic stellate cells.
2006 Oct
[Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin].
2006 Sep
Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors.
2007
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
2007 Apr
Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma.
2007 Feb
Effect of pioglitazone treatment on behavioral symptoms in autistic children.
2007 Jan 5
The PPARgamma agonist pioglitazone inhibits early neoplastic occurrence in the rat liver.
2007 Jul
Ligands of peroxisome proliferator-activated receptor inhibit homocysteine-induced DNA methylation of inducible nitric oxide synthase gene.
2007 May
Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice.
2007 May
Inhibitory effect of PPAR on the expression of EMMPRIN in macrophages and foam cells.
2007 May 2
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
2007 Sep 12
Treating Hispanic patients for type 2 diabetes mellitus: special considerations.
2008 May
Bezafibrate prevents hepatic stellate cell activation and fibrogenesis in a murine steatohepatitis model, and suppresses fibrogenic response induced by transforming growth factor-beta1 in a cultured stellate cell line.
2008 Oct
Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes.
2008 Sep
Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro.
2009 Apr
Type 2 deiodinase expression is induced by peroxisomal proliferator-activated receptor-gamma agonists in skeletal myocytes.
2009 Apr
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
2009 Dec 3
Retinol saturase promotes adipogenesis and is downregulated in obesity.
2009 Jan 27
Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
2009 May
Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes.
2009 Oct 30
Computer-aided discovery, validation, and mechanistic characterization of novel neolignan activators of peroxisome proliferator-activated receptor gamma.
2010 Apr
Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.
2010 Feb
Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
2010 Jul 9
Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants.
2010 May
Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice.
2010 Sep 25
Patents

Sample Use Guides

Initiate ACTOS (Pioglitazone) at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II heart failure. If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily.
Route of Administration: Oral
For the cell counting assay, Human aortic smooth muscle cells (HASMCs) were seeded at 3× 10^3 cells on to a 96-well dish; 24 hours after the plating, the cells were serum-starved to render them quiescent by replacing the medium with DMEM containing 0.2% FBS. The quiescent SMCs were then preincubated with globular adiponectin (1μg/mL or 3μg/mL) or pioglitazone (1μM or 10μM) for 30min. PDGF-BB (10ng/mL) was added to stimulate the cells for 24hours. These cells were incubated with 10 μl of CCK (cell counting kit)-8 (DOJINDO) or WST-1 (Roche) solution for 2hours before conducting the measurements. We measured the absorbance at 450nm using a microplate reader. 10 μl of BrdU (Roche) solution was added these cells simultaneously with PDGF-BB. BrdU incorporation was measured by chemiluminescent assay
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:18:57 GMT 2023
Edited
by admin
on Sat Dec 16 16:18:57 GMT 2023
Record UNII
X4OV71U42S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIOGLITAZONE
EMA EPAR   HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
5-(4-(2-(5-ETHYLPYRIDIN-2-YL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE
Systematic Name English
PIOGLITAZONE [MI]
Common Name English
pioglitazone [INN]
Common Name English
ZACTOS
Brand Name English
5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
AD-4833
Code English
PIOGLITAZONE [EMA EPAR]
Common Name English
PIOGLITAZONE [VANDF]
Common Name English
(RS)-5-(4-(2-(5-ETHYLPYRIDIN-2-YL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE
Systematic Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-, (±)-
Systematic Name English
PIOGLITAZONE [HSDB]
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-
Systematic Name English
PIOGLITAZONE [IARC]
Common Name English
GLUSTIN
Brand Name English
Pioglitazone [WHO-DD]
Common Name English
U-72107
Code English
(±)-5-(P-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE
Common Name English
5-(4-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000170118
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
WHO-VATC QA10BD09
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
FDA ORPHAN DRUG 583017
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NDF-RT N0000170119
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
LIVERTOX NBK548327
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
WHO-ATC A10BD05
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
WHO-VATC QA10BD06
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NDF-RT N0000180186
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
EU-Orphan Drug EU/3/14/1245
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NCI_THESAURUS C98241
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NDF-RT N0000170118
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NDF-RT N0000175374
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NDF-RT N0000170119
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
WHO-ATC A10BD12
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NDF-RT N0000011272
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NDF-RT N0000011272
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
WHO-ATC A10BD09
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NDF-RT N0000180190
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
WHO-ATC A10BG03
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
WHO-VATC QA10BG03
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NDF-RT N0000011272
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
WHO-VATC QA10BD05
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
WHO-ATC A10BD06
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
WHO-VATC QA10BD12
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
NDF-RT N0000175596
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
Code System Code Type Description
DRUG CENTRAL
2179
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
NCI_THESAURUS
C71633
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
DAILYMED
X4OV71U42S
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
MERCK INDEX
m8835
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY Merck Index
PUBCHEM
4829
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
CAS
111025-46-8
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
INN
6343
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
CAS
105355-27-9
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
SUPERSEDED
SMS_ID
100000085494
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
ChEMBL
CHEMBL595
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
WIKIPEDIA
PIOGLITAZONE
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
EPA CompTox
DTXSID3037129
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
CHEBI
8228
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
EVMPD
SUB09857MIG
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
IUPHAR
2694
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
FDA UNII
X4OV71U42S
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
RXCUI
33738
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY RxNorm
HSDB
7322
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
CAS
198077-89-3
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
SUPERSEDED
LACTMED
Pioglitazone
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
DRUG BANK
DB01132
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
MESH
C060836
Created by admin on Sat Dec 16 16:18:58 GMT 2023 , Edited by admin on Sat Dec 16 16:18:58 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
IC50
TARGET -> AGONIST
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC